摘要
目的:研究促性腺激素释放激素(GnRH-a)联合左炔诺孕酮宫内释放系统(LNG-IUS)对子宫腺肌症(AM)患者血清癌抗原125(CA125)、血管内皮生长因子(VEGF)、女性卵泡刺激素(FSH)和黄体生成素(LH)的影响及疗效探究。方法:选取我院2015年6月至2017年6月进行临床治疗的子宫腺肌症患者60例,根据治疗方案不同分为观察组和对照组,对照组实施子宫切除术,观察组给予GnRH-a联合LNG-IUS治疗。分明观察两组患者治疗后临床疗效及不良反应,并检测治疗前后血清CA125、VEGF、FSH和LH水平以及观察患者痛经、子宫体积和月经量。结果:治疗后,观察组总有效率(90.0%)明显高于对照组(73.3%)(P<0.05);观察组血清CA125、VEGF、FSH和LH水平均显著低于对照组(P<0.05);观察组痛经评级、子宫体积和月经量明显低于对照组(P<0.05);且观察组不良反应发生率6.7%明显低于对照组不良反应率26.7%(P<0.05)。结论:GnRH-a联合LNG-IUS治疗AM患者,有效降低患者血清CA125、VEGF、FSH和LH水平和降低痛经评级、子宫体积和月经量评分,且可减少不良反应。
Objective:To study curative efficacy of GnRH-a combined with LNG-IUS in treatment of uterine adenomyosis and its effects on level of CA125,VEGF,FSH and LH.Methods:60 patients of uterine adenomyosis who received therapy from June 2015 to June 2017 in our hospital were selected as research objects.According to the different treatment plan divided into observation group and control group,the control group to hysterectomy,the observation group given GnRH-a combined with LNG-IUS treatment.The levels of serum CA125,VEGF,FSH and LH were measured before and after treatment,and the dysmenorrhea,uterine volume and menstrual flow were observed.Results:After treatment,the total effective rate(90.0%)in the observation group was significantly higher than that in the control group(73.3%)(P<0.05).The levels of serum CA125,VEGF,FSH and LH were significantly lower than those in the control group(P<0.05).The incidence of dyspepsia in the observation group was significantly lower than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05)The reaction rate was 26.7%,and the difference was significant(P<0.05).Conclusion:Shenfu injection unite recombinant human brain natriuretic peptide treatment of patients with chronic heart failure can effectively improve on cardiac function,the BNP,mmp-9,CypA levels were to reduce,significantly improve the clinical curative effect,and can reduce adverse reaction.GnRH-a combined with LNG-IUS treatment of patients with AM,effectively reduce serum CA125,VEGF,FSH and LH levels and reduce dysmenorrhea rating,uterine volume and menstrual score,and can reduce adverse reactions.
作者
齐进
邓晓红
QI Jin;DENG Xiaohong(Northwest Women and Children's Hospital,Shaanxi Xi'an 710061,China)
出处
《河北医学》
CAS
2018年第10期1615-1619,共5页
Hebei Medicine
基金
陕西省自然科学基金项目
(编号:20111071)
